Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13994868 | 0.89 | KMT2A (0.53) | KMT2AMEN1USP30HDAC4EPHX2 | |
| SCHEMBL723951 | 0.86 | CRBN (0.51) | KMT2AMEN1USP30HDAC4EPHX2 | |
| SCHEMBL247897 | 0.85 | MAPT (0.59) | KMT2AMEN1USP30CRBNALDH1A1 | |
| SCHEMBL19126438 | 0.84 | MEN1 (0.47) | KMT2AMEN1USP30HDAC4EPHX2 | |
| SCHEMBL17404601 | 0.84 | USP30 (0.47) | KMT2AMEN1USP30ABL1RIN1 | |
| SCHEMBL3731796 | 0.84 | ALDH1A1 (0.43) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL13336464 | 0.83 | MEN1 (0.53) | KMT2AMEN1USP30HDAC4EPHX2 | |
| SCHEMBL3726024 | 0.83 | USP30 (0.48) | KMT2AMEN1USP30HDAC4EPHX2 | |
| SCHEMBL31267764 | 0.82 | MAPT (0.57) | KMT2AMEN1USP30EPHX2ABL1 | |
| SCHEMBL3123517 | 0.82 | USP30 (0.50) | KMT2AMEN1USP30MAPTAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025128805-A1 | A CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-3577116-B1 | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-A]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | CHANGZHOU QIANHONG BIO PHARMA CO LTD (CN) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025037870-A1 | BENZOFURAN COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASES AND CANCER METASTASIS | 한국생명공학연구원 | 2025-02-20 | — | — | WO | disclosed |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-02 | — | — | US | disclosed |
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-114867718-B | Indazole derivatives and use thereof | 韩国化学研究院 | 2024-10-01 | — | — | CN | disclosed |
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OFCHEMICAL TECHNOLOGY (KR) | 2023-04-13 | — | — | US | disclosed |
| EP-4079732-A1 | NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2022-10-26 | — | — | EP | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2379561-A2 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110224191-A1 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines | OSI Pharmaceuticals, LLC | 2011-09-15 | — | — | US | disclosed |
| EP-2356116-A1 | SUBSTITUTED PYRROLOÝ2,3-B¨-PYRIDINES AND-PYRAZINES | OSI Pharmaceuticals, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010059771-A1 | SUBSTITUTED PYRROLO[2,3-B]-PYRIDINES AND-PYRAZINES | OSI PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-7465842-B2 | Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | KMT2A 587/4885MEN1 1723/4885USP30 2357/4885 |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | SSB, IDO1, IDO2 | KMT2A 2152/4885MEN1 2610/4885USP30 3236/4885 |
| US-20110224191-A1 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines | MET, RET, KRAS | KMT2A 2030/4885MEN1 121/4885USP30 4242/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | KMT2A 3953/4885MEN1 1933/4885USP30 3990/4885 |
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | TRIB2, YAP1, IDO2 | KMT2A 1433/4885MEN1 3559/4885USP30 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.